Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Follitropin delta

  • Home
  • Follitropin delta
Cumulative Live Birth Rates Plateau at 21–25 Oocytes: New Insights from Follitropin Delta Trials
Posted innews OB/GYN & Women's Health

Cumulative Live Birth Rates Plateau at 21–25 Oocytes: New Insights from Follitropin Delta Trials

Posted by MedXY By MedXY 12/26/2025
A pooled analysis of 1,746 patients demonstrates that while fresh cycle success peaks early, cumulative live birth rates continue to rise with oocyte yield, plateauing at 21–25 oocytes. This benefit is most pronounced in patients aged 38 and older, suggesting age-specific stimulation targets.
Read More
  • A New CTCL-Specific Quality-of-Life Tool Shows Strong Early Validity Signals in Cutaneous T-Cell Lymphoma
  • CAR T-Cell Therapy Targeting CD117 Shows Promise Against Advanced Systemic Mastocytosis in Preclinical Studies
  • Study Finds Infusion Timing Does Not Affect CAR T-Cell Therapy Outcomes for Large B-Cell Lymphoma
  • A GOLD Science Committee Perspective on Exacerbations and Cardiovascular Risk In COPD
  • Genotype-phenotype correlations in RPGRIP1-associated retinal dystrophy in a nationwide Japanese cohort
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in